WAILEA, Hawaii — Changes in CMS reimbursement is affecting many of the ophthalmic subspecialties this year.
Important for cataract surgery is the expiration of the pass-through status for Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution, Omeros).
Omidria, which has been used for the past 3 years with pass through status for Medicare payment, can no longer be billed in any fashion as of January 1, when the pass-through expired, Kevin J. Corcoran, COE, CPC, CPMA, FNAO, said at Hawaiian Eye 2018, where he gave on update on coding and (Read more...)
Uncategorized